Saturday, January 23, 2021
Financing and M&A

Amgen Announces Additional Investment of $421M In BeiGene

Amgen (NASDAQ:AMGN) today announced an additional investment of approximately $421 million in BeiGene’s registered direct offering of ordinary shares, which maintains Amgen’s current pro rata ownership of BeiGene at approximately 20.3%.  This additional investment reflects Amgen’s confidence in the progress the companies are making in their ongoing oncology collaboration in China, the world’s second largest pharmaceutical market.  

19 thoughts on “Amgen Announces Additional Investment of $421M In BeiGene
  1. Pingback: tennis truc tuyen
  2. Pingback: pubg cheats
  3. Pingback: Devops solutions
  4. Pingback: 토토사이트
  5. Pingback: dumps cc sites
  6. Pingback: fakerolex.ru
  7. Pingback: chiem bao thay voi
  8. Pingback: everreplica.com

Leave a Reply

Your email address will not be published.